{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:17:50Z","timestamp":1787897870826,"version":"build-2784847793"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Drug Deliv."],"abstract":"<jats:p>\n                    A 45-year-old female Jehovah\u2019s Witness presented with transient expressive aphasia, blurred vision, and dizziness for several hours. A complete blood count (CBC) showed anemia (hemoglobin: 6.3\u00a0g\/dL), thrombocytopenia (platelet count: 21 \u00d7 10\n                    <jats:sup>3<\/jats:sup>\n                    \/\u00b5L), and undetectable haptoglobin. The peripheral smear revealed schistocytes, confirming microangiopathic hemolytic anemia; immune-mediated thrombotic thrombocytopenic purpura (iTTP) was confirmed with an ADAMTS13 level of less than 5% and a positive ADAMTS13 inhibitor screen. Treatment with high-dose corticosteroids was urgently initiated, but the patient and her husband declined plasma exchange based on their beliefs as Jehovah\u2019s Witnesses. The patient acutely decompensated, requiring intubation, with worsening of laboratory values (hemoglobin: 3.8\u00a0g\/dL; platelet count: 9 \u00d7 10\n                    <jats:sup>3<\/jats:sup>\n                    \/\u00b5L), elevated serum troponin, and renal and hepatic compromise. In addition to rituximab and intravenous immune globulin, caplacizumab therapy was undertaken. The patient\u2019s condition improved clinically, but from a laboratory value perspective, 1\u00a0month after caplacizumab initiation, her ADAMTS13 level remained less than 5%. Further immunosuppression with intravenous cyclophosphamide was initiated, which resulted in complete normalization of ADAMTS13 activity. This is the first report of caplacizumab use in a Jehovah\u2019s Witness patient with TTP with severe neurological compromise to the point of necessitating intubation and with this degree of anemia. With the eventual addition of cyclophosphamide therapy, we observed complete recovery of this critically ill patient without the use of plasma exchange in the treatment course.\n                  <\/jats:p>","DOI":"10.3389\/fddev.2026.1894135","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:33:47Z","timestamp":1787895227000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case report: Caplacizumab without plasma exchange for severe thrombotic thrombocytopenic purpura"],"prefix":"10.3389","volume":"6","author":[{"given":"Sarah Maryon","family":"Hayes","sequence":"first","affiliation":[{"name":"North Memorial Health, Cancer Center","place":["Robbinsdale, MN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Pease","sequence":"additional","affiliation":[{"name":"North Memorial Health, Cancer Center","place":["Robbinsdale, MN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Wiese","sequence":"additional","affiliation":[{"name":"North Memorial Health, Cancer Center","place":["Robbinsdale, MN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall","family":"Mazepa","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Transplantation, University of Minnesota \u2013 Department of Medicine","place":["Minneapolis, MN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1111\/j.1537-2995.2012.03578.x","article-title":"Thrombotic microangiopathies reference center. Splenectomy And\/Or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA reference center experience","volume":"52","author":"Beloncle","year":"2012","journal-title":"Transfusion"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e05902","DOI":"10.1002\/ccr3.5902","article-title":"Immune-mediated thrombotic thrombocytopenic purpura in a Jehovah's witness - Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab","volume":"10","author":"Cardesa-Salzmann","year":"2022","journal-title":"Clin. Case Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1056\/NEJMc1905426","article-title":"Caplacizumab therapy without plasma exchange for acquired thrombotic thrombocytopenic purpura","volume":"381","author":"Chander","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/asheducation-2018.1.530","article-title":"Clinical and laboratory diagnosis of TTP: an integrated approach","volume":"2018","author":"Chiasakul","year":"2018","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B6","article-title":"Caplacizumab and immunosuppression without plasma exchange in thrombotic thrombocytopenic purpura. Abstract LB 01.5","volume-title":"Presented at the International Society on Thrombosis and Haemostasis (ISTH) 2025 Congress","author":"Coppo","year":"2025"},{"key":"B7","doi-asserted-by":"publisher","first-page":"005","DOI":"10.46998\/IJCMCR.2021.10.000245","article-title":"Acquired thrombotic purpura successfully treated with caplacizumab without plasma transfusion in a Jehovah\u2019s witness patient","volume":"10","author":"Desai","year":"2021","journal-title":"Int. J. Clin. Stud. and Med. Case Rep"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e12658","DOI":"10.1002\/rth2.12658","article-title":"Clinical relapse of immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination","volume":"6","author":"Deucher","year":"2022","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1111\/trf.15823","article-title":"Caplacizumab for treatment of thrombotic thrombocytopenic purpura in a patient with anaphylaxis to fresh-frozen plasma","volume":"60","author":"Irani","year":"2020","journal-title":"Transfusion"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1182\/blood.2023023780","article-title":"Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange","volume":"144","author":"K\u00fchne","year":"2024","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1002\/pbc.24612","article-title":"Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features","volume":"60","author":"Reese","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"B13","unstructured":"Religious and ethical position on medical therapy and related matters\n          \n          \n          2025"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e502","DOI":"10.1097\/MJT.0000000000001522","article-title":"Caplacizumab without plasma exchange for thrombotic thrombocytopenic purpura in a Jehovah's witness [published online ahead of print, 2022 may 26]","volume":"30","author":"Spencer","year":"2022","journal-title":"Am. J. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"E76","DOI":"10.1002\/ajh.25715","article-title":"Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab","volume":"95","author":"Sukumar","year":"2020","journal-title":"Am. J. Hematol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1182\/blood-2010-11-317859","article-title":"Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs","volume":"118","author":"Ulrichts","year":"2011","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1111\/jth.15045","article-title":"Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab","volume":"18","author":"V\u00f6lker","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"B18","doi-asserted-by":"publisher","first-page":"11230","DOI":"10.1182\/blood-2022-162837","article-title":"Caplacizumab treatment, without plasma exchange, of a Jehovah's witness with thrombotic Thrombocytopenia purpura resulted in rapid and durable remission: a case report","volume":"140","author":"Warr","year":"2022","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J. Thromb. Haemost."}],"container-title":["Frontiers in Drug Delivery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fddev.2026.1894135\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:33:48Z","timestamp":1787895228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fddev.2026.1894135\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":19,"alternative-id":["10.3389\/fddev.2026.1894135"],"URL":"https:\/\/doi.org\/10.3389\/fddev.2026.1894135","relation":{},"ISSN":["2674-0850"],"issn-type":[{"value":"2674-0850","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"article-number":"1894135"}}